Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ny developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... 2014 Texas Governor Rick Perry, ... A&M Health Science Center CEO Brett Giroir, M.D., ... and Human Services (HHS), State of Texas and ... influenza vaccine manufacturing facility in Bryan, Texas, which ... the Texas A&M Biocorridor – a rapidly evolving ...
(Date:9/18/2014)... Research and Markets has announced the addition ... In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to ... The global companion diagnostics market is expected to grow ... Factors such as rising need for personalized medicine in ... pharmaceutical industry, support from regulatory authorities, and emerging technologies ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... (Amex: CPD ) announced the resignation as a ... appointment as a Director of the,Company of Gurpartap ("GP") ... the Company, effective July 22, 2008., Prior to ... July 2007, Mr. Singh served as Vice President - ...
... new CEO,Andrew Witty comments on GSK,s second quarter results while ... The new strategic priorities for GlaxoSmithKline ... Deliver more products of value - Simplify GSK,s operating ... on, http://www.cantos.com . It,s free to view. All you need ...
... retraction needed for surgical ... ... the market availability of the SlimFuse(TM) Anterior,Cervical Plate System. This innovative ... clinical needs of,anterior cervical discectomy and fusion (ACDF) surgery., SlimFuse(TM) ...
Cached Biology Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva 2Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System 2
(Date:9/18/2014)... found clownfish larvae can swim up to 400 kilometres in ... cope with environmental change. , Clownfish spend their entire adult ... babies they must wander the open ocean, says study co-author, ... Coral Reef Studies (Coral CoE) at James Cook University. , ... now we,ve been given a rare glimpse into how far ...
(Date:9/17/2014)... creation of the Santa Ana Wildfire Threat Index ... of the powerful, hot, dry Santa Ana wind, which ... was introduced Sept. 17 by the U.S. Forest Service, ... Electric. , The index includes four classification levels ranging ... help fire agencies and other emergency responders, the media ...
(Date:9/17/2014)... Europaea started in 2000 as an EC-FP5 four-year project, ... of steady progress and successful participations in several EC ... Biodiversity Observation Network project (EU BON), to increase ... contributors and to extend the general dissemination of the ... has applied its novel e-Publishing tools to ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... a paper published this week in the Proceedings ... aquatic ecologist Dr. Emma Rosi-Marshall and colleagues report that ... proteins that originate from adjacent genetically modified crops. The ... stalks, and plant parts are washed into stream channels. ...
... and global contributions to clean water and environmental causes, ... to invention and the pursuit of discovery, Professor Xiaoguang ... Stevens Institute of Technology at the university,s annual Convocation ... professor in the Charles V. Schaefer, Jr. School of ...
... Elevated concentrations of nitrogen and phosphorus, nutrients that can ... the same or increased in many streams and aquifers ... a new national study by the U.S. Geological Survey. ... assessment to date of nitrogen and phosphorus in our ...
Cached Biology News:Insecticides from genetically modified corn present in adjacent streams 2Prof. Xiaoguang Meng receives honorary master of engineering from Stevens 2Prof. Xiaoguang Meng receives honorary master of engineering from Stevens 3Elevated nitrogen and phosphorus still widespread in much of the nation's streams and groundwater 2Elevated nitrogen and phosphorus still widespread in much of the nation's streams and groundwater 3
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
Hybridization cassette for one slide...
... Tissues are selected tissues from mouse, rat, ... embedded in paraffin, sectioned and mounted onto ... are ready for use in tissue RNA ... tissue slides are suitable for in situ ...
MHC Volumes 1 & 2...
Biology Products: